AstraZeneca R&D Gothenburg Sweden

Prof. Martin Hayes

AstraZeneca is a global, science-led, patient-focused pharmaceutical company focusing on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, renal, respiratory, immunological, rare diseases and oncology. AstraZeneca is also selectively active in the areas of autoimmunity, neuroscience and infection.
AstraZeneca operates in over 100 countries. The innovative portfolio of medicines of AstraZeneca impact more than 120 million patient lives annually.
The company has 83,000 employees with approximately 14,000 employees in the R&D organization and invested 9.7 bn$ in R&D in 2021, i.e. more than a quarter of the total revenues (37.4 bn$). Two of the three strategic R&D centres are located in Europe, in Cambridge UK and Gothenburg Sweden. The third R&D hub is located in Gaithersburg, MD, US.


Key expertise

Biocatalysis, drug discovery, drug design, drug metabolism and pharmacokintetics




Relevant Publications

1)     Oxalate Oxidase for In Situ H2O2-generation in Unspecific Peroxygenase-Catalysed Drug Oxyfunctionalisations Romero E., (2022), Angew. Chem. Int. Ed. Engl.

2)     Biocatalysis, Bell E. L. et al, (2021), Nat. Rev. Methods Primers

3)     Enzymatic Late‐Stage Modifications: Better Late Than Never, Romero, E. et alAngew. Chem. Int. Ed. Engl. 202160, 16824.

4)     Biocatalytic Monoacylation of Symmetrical Diamines and its Application to the Synthesis of Pharmaceutically Relevant Amides, Lubberink, M. et al, ACS Catal. (2020), 10, 17, 10005.

5)     Engineering of CYP2D enzymes for biocatalysis using combinatorial libraries of ancestors for directed evolution (CLADE), Gumulya, Y. et al , ChemCatChem., (2019),